The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan

BACKGROUND: Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed‐dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection. Our study evaluates the clinical efficacy and safety of EBR/GZR after its launch in Taiwan. METHODS: This is a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Tzu‐Cheng, Deng, Shin‐Tarng, Hsu, Chao‐Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916308/
https://www.ncbi.nlm.nih.gov/pubmed/31599455
http://dx.doi.org/10.1002/jmv.25605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916308/
https://www.ncbi.nlm.nih.gov/pubmed/31599455
http://dx.doi.org/10.1002/jmv.25605

Ejemplares similares